PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

CPHI 2027
AI in Drug Discovery
Auto Draft
Auto Draft
Elrig
Auto Draft
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

Exploring the 505(b)(2) Route for Systemic and Regional Therapy via Pulmonary Delivery

The Advantages of Using Respirable Engineered Spray-dried Dry Powder

Inhaled drug products offer several advantages over other dosage forms, including more targeted drug delivery, which can mean a lower dose is required, in turn reducing side-effects. Developing generic versions of complex products is increasingly challenging and it is important to consider a regulatory strategy to achieve market approval as quickly and efficiently as possible, using a simple and efficient pathway. In this article,  Aditya R. Das at Recipharm explores the use of the 505(b)(2) application route to advance inhalation drugs to market and the advantages of using respirable engineered spray-dried powder for the development of these products.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2018/12/Exploring-the-505b2-route-for.pdf” width=”100%” height=”900px” style=”border:0;”]

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC